Insider Selling: National Research Co. (NASDAQ:NRC) Major Shareholder Sells 1,322 Shares of Stock

National Research Co. (NASDAQ:NRCGet Rating) major shareholder Amandla Mk Trust sold 1,322 shares of the business’s stock in a transaction on Tuesday, April 19th. The shares were sold at an average price of $39.90, for a total transaction of $52,747.80. Following the sale, the insider now directly owns 5,934,272 shares in the company, valued at approximately $236,777,452.80. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Amandla Mk Trust also recently made the following trade(s):

  • On Friday, April 8th, Amandla Mk Trust sold 600 shares of National Research stock. The shares were sold at an average price of $40.02, for a total transaction of $24,012.00.
  • On Wednesday, April 6th, Amandla Mk Trust sold 8,137 shares of National Research stock. The stock was sold at an average price of $40.71, for a total transaction of $331,257.27.
  • On Monday, April 4th, Amandla Mk Trust sold 2,500 shares of National Research stock. The stock was sold at an average price of $40.15, for a total transaction of $100,375.00.

NASDAQ NRC traded down $1.43 during trading on Thursday, hitting $38.29. 26,884 shares of the company’s stock traded hands, compared to its average volume of 45,095. The stock has a fifty day moving average of $39.09 and a two-hundred day moving average of $41.09. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.83 and a quick ratio of 1.82. National Research Co. has a 12-month low of $36.29 and a 12-month high of $55.67. The firm has a market cap of $964.68 million, a P/E ratio of 26.26 and a beta of 0.70.

National Research (NASDAQ:NRCGet Rating) last posted its quarterly earnings results on Tuesday, February 8th. The company reported $0.38 earnings per share (EPS) for the quarter. National Research had a net margin of 25.32% and a return on equity of 47.12%. The business had revenue of $38.30 million during the quarter.

The company also recently announced a quarterly dividend, which was paid on Friday, April 15th. Stockholders of record on Thursday, March 31st were issued a dividend of $0.24 per share. This is a positive change from National Research’s previous quarterly dividend of $0.12. This represents a $0.96 dividend on an annualized basis and a dividend yield of 2.51%. The ex-dividend date of this dividend was Wednesday, March 30th. National Research’s dividend payout ratio is currently 65.31%.

Several institutional investors have recently bought and sold shares of the company. Glenmede Trust Co. NA boosted its holdings in shares of National Research by 6.0% during the fourth quarter. Glenmede Trust Co. NA now owns 5,642 shares of the company’s stock worth $234,000 after purchasing an additional 319 shares during the period. Voya Investment Management LLC boosted its holdings in shares of National Research by 5.9% during the third quarter. Voya Investment Management LLC now owns 6,002 shares of the company’s stock worth $253,000 after purchasing an additional 336 shares during the period. California State Teachers Retirement System boosted its holdings in shares of National Research by 2.2% during the fourth quarter. California State Teachers Retirement System now owns 19,437 shares of the company’s stock worth $807,000 after purchasing an additional 426 shares during the period. Precision Wealth Strategies LLC boosted its holdings in shares of National Research by 9.2% during the fourth quarter. Precision Wealth Strategies LLC now owns 6,070 shares of the company’s stock worth $252,000 after purchasing an additional 513 shares during the period. Finally, Credit Suisse AG lifted its holdings in National Research by 3.7% in the third quarter. Credit Suisse AG now owns 15,395 shares of the company’s stock worth $649,000 after buying an additional 551 shares during the period. Institutional investors own 68.68% of the company’s stock.

Separately, TheStreet cut shares of National Research from a “b-” rating to a “c+” rating in a report on Tuesday, January 18th.

About National Research (Get Rating)

National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience in the United States and Canada. Its portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, health risk assessments, employee engagement, reputation management, and brand loyalty.

See Also

Insider Buying and Selling by Quarter for National Research (NASDAQ:NRC)

Receive News & Ratings for National Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for National Research and related companies with MarketBeat.com's FREE daily email newsletter.